SAGE Therapeutics Inc (SAGE) was Resumed by Leerink Partners to “Outperform” and the brokerage firm has set the Price Target at $68. Leerink Partners advised their investors in a research report released on Oct 4, 2016.
Many Wall Street Analysts have commented on SAGE Therapeutics Inc. Raymond James Initiated SAGE Therapeutics Inc on Sep 13, 2016 to “Outperform”, Price Target of the shares are set at $75.
SAGE Therapeutics Inc opened for trading at $45.87 and hit $47 on the upside on Friday, eventually ending the session at $46.05, with a gain of 1.14% or 0.52 points. The heightened volatility saw the trading volume jump to 7,46,785 shares. Company has a market cap of $1,478 M.
In a different news, on Sep 9, 2016, Kimi Iguchi (CFO, Secretary and Treasurer) sold 2,500 shares at $40.93 per share price. According to the SEC, on Jul 14, 2016, Albert Robichaud (Chief Scientific Officer) sold 22,000 shares at $40.00 per share price. On Apr 21, 2016, Stephen Kanes (Chief Medical Officer) sold 21,000 shares at $38.00 per share price, according to the Form-4 filing with the securities and exchange commission.
SAGE Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening rare central nervous system (CNS) disorders. The Company’s lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.